Alternative technique for reducing compound waste during intravitreal injections

Abstract

Purpose:To describe an intravitreal injection technique using a commercially available 29-gauge insulin needle syringe (29GN syringe) and a 21-gauge (G) needle, comparing compound waste associated with this technique application and the one described in ranibizumab (Lucentis ® ) kit instructions. Methods: Ten 0.3 ml doses of distilled water were aspirated using the 29GN syringe and 21G needle (PT technique), and another ten equal doses were aspirated employing the sterilized Lucentis ® kit (LK technique), which contains a 1ml tuberculin syringe, a 18G needle for compound aspiration and a 30G needle for intravitreal injection. For aspiration using the PT technique, a 21G needle is attached over a 29GN syringe. After compound aspiration, the 21G needle is removed and intravitreal injection is performed using the 29G needle. Using a precision balance, the aspiration needles (21G for PT; 18G for LK) were weighed before and after water aspiration and the syringe-needle complexes for injection (29GN for PT; 30G for LK) were weighed before aspiration and after emptying them. The volumes left in the aspiration needles and needlesyringe complexes were estimated by the difference in weight in grams, which were converted to millilitres. Results: The mean (±SD) residual volume (ml) of aspiration needles (21G for PT; 18G for LK) was significantly lower with PT technique (0.0034 ± 0.0016) when compared to LK tech nique (0.0579 ± 0.0011) (p<0.01). The mean (±SD) residual volume (ml) of syringe-needle complexes was significantly lower with PT technique (0.0056 ± 0.0011) than with LK (0.0906 ± 0.003 ml) (p<0.01). Conclusion:The proposed technique is a reasonable alternative for minimizing medication loss during intravitreal injection procedures. ABSTRACT INTRODUCTION

A Prospective Randomized Trial of Intravitreal Bevacizumab Versus Ranibizumab for the Management of Diabetic Macular Edema

“…Bevacizumab (1.5 mg/0.06 cc; F. Hoffmann-La Roche Ltd., Basel, Switzerland) or ranibizumab (0.5 mg/ 0.05 cc; Novartis Pharma Stein AG, Stein, Switzerland) was injected into the vitreous cavity using a 29-gauge 0.5inch needle inserted through the inferotemporal pars plana 3.0-3.5 mm posterior to the limbus. 21 After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill 1 drop of 0.3% ciprofloxacin into the injected eye 4 times daily for 1 week after the procedure.…”

Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy

“…For the 20 eyes selected to receive combined treatment, PRP plus IVR (PRP plus ), one intravitreal injection of 0.5 mg (0.05 ml) of ranibizumab was performed approximately 60 min after the completion of the first PRP session (at week 0) by a single retinal specialist (JARF). Ranibizumab was injected into the vitreous cavity via a 29‐gauge needle inserted through the inferotemporal pars plana 3.0–3.5 mm posterior to the limbus using topical proparacaine drops under sterile conditions (eyelid speculum and povidone‐iodine) (Ribeiro et al. 2009).…”

Intravitreal Injection of Ranibizumab During Cataract Surgery in Patients With Diabetic Macular Edema

“…16 The phacoemulsification procedure included the following steps: 3.0-mm clear corneal incision, "stop and chop" phacoemulsification technique (Legacy; Alcon), type 7B foldable intraocular lens (Alcon) insertion, and 1 NYLON 10.0 stitch to close the clear corneal incision.…”